Advertisement

Topics

UMI3 gives exclusive licence for SenTraGor to Arriani Pharmaceuticals

19:00 EDT 23 Aug 2017 | Pharmaceutical Technology

The University of Manchester’s technology transfer company, UMI3, has entered an exclusive licence deal with Arriani Pharmaceuticals for a research tool that helps clarify the role of senescent cells in several age-related diseases, including cancer.

Original Article: UMI3 gives exclusive licence for SenTraGor to Arriani Pharmaceuticals

NEXT ARTICLE

More From BioPortfolio on "UMI3 gives exclusive licence for SenTraGor to Arriani Pharmaceuticals"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...